Medtronic, Inc. Enters Distribution Agreement with Miami Instruments, LLC
January 27, 2012 at 09:00 am
Share
Medtronic, Inc. announced that it has entered into an exclusive distribution agreement with Miami Instruments, LLC and has introduced the company's first two products in the U.S. The first products launched are the Joseph Lamelas Knot Pusher(TM), which is designed to simplify the delivery and tying of secure suture knots in the heart during MICS procedures, and the Joseph Lamelas Atrial Lift System(TM), which is used to retract the atrial wall during limited-access cardiac surgical procedures. These products are registered with the FDA and are available for use in the U.S. Each year more than 400,000 heart valve repair and valve replacement procedures are performed throughout the world. These procedures are typically performed through open-heart surgery, which requires a surgical incision through a patient's breastbone and the use of a heart-lung machine. Specially trained cardiac surgeons are performing heart valve repairs and replacements using MICS, and these techniques allow access to the heart through smaller incisions using specialized, minimally invasive surgical instruments and without separating the breastbone. MICS procedures typically allow for reduced blood loss during surgery, quicker patient recovery times and shorter hospital stays.
Medtronic plc is one of the world leaders in designing, manufacturing and marketing of medical equipment. Net sales break down by sector of activity as follows:
- general and minimally invasive surgery (28.8%): surgical equipment, intra-operative monitoring systems, ventilation systems, etc.;
- cardiac rhythm management (18.6%): implantable cardiac pacemakers, implantable defibrillators and automatic external defibrillators, cardiac ablation probes, etc.;
- vascular diseases and cardiac surgery (17.4%): coronary stents, endoprostheses for aortal pathologies, distal protection systems, catheters, heart valve prostheses, auto-transfusion equipment, cardiac ablation devices, etc.;
- spinal disorders (14.1%): spinal prostheses, disc prostheses, cerebral stimulation systems, bone graft technologies and mini-invasive spinal surgery, etc. The group also develops medical imagery-guided surgical navigation systems activity;
- neurovascular, ear, nose and throat (ENT) and pelvic diseases (8.2%);
- diabetes management (7.4%): internal and external glycemia monitoring systems and insulin pumps;
- neurological disorders (5.5%): neurostimulation and pumped medication administration products, diagnostic tools, etc.
Net sales are distributed geographically as follows: Ireland (0.3%), the United States (50.9%) and other (48.8%).